行情

FTSV

FTSV

Forty Seven
NASDAQ

实时行情|Nasdaq Last Sale

5.97
+0.13
+2.23%
盘后: 5.97 0 0.00% 16:00 10/11 EDT
开盘
5.89
昨收
5.84
最高
6.20
最低
5.89
成交量
15.82万
成交额
--
52周最高
23.83
52周最低
5.69
市值
1.77亿
市盈率(TTM)
-1.9302
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FTSV 新闻

  • 特朗普回答中国日报提问 称将查看“实体清单”
  • 新浪财经综合.1天前
  • 特朗普回应:中国留学生不会被区别对待
  • 人民日报.1天前
  • 联合国将采取节支措施以应对严重财务危机
  • 新华社.1天前
  • 万亿美金的苹果 在乐视的路上越走越远
  • 新浪财经-自媒体综合.1天前

更多

所属板块

生物技术和医学研究
+0.89%
制药与医学研究
+0.89%

热门股票

名称
价格
涨跌幅

FTSV 简况

Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
展开

Webull提供Forty Seven Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。